Mazdutide: all 40 studies that test it

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Mazdutide for Weight Management and Gout in Adults With ObesityNot yet recruitingNCT07824895Phase 4
• Efficacy of Mazdutide on Fatty PancreasNot yet recruitingNCT07803705Not applicable
• Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNot yet recruitingNCT07797101Not applicable
• Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNot yet recruitingNCT07781150Phase 2
• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNot yet recruitingNCT07775846Phase 4
• Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled TrialNot yet recruitingNCT07767552Not applicable
• Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)RecruitingNCT07718126Phase 4
• Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNot yet recruitingNCT07713992Not applicable
• Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityRecruitingNCT07657676Phase 4
• Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)Not yet recruitingNCT07654062Phase 4
• ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementRecruitingNCT07517042Not applicable
• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3
• A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingNCT07255209Phase 3
• Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)RecruitingNCT07083154Phase 3
• A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingNCT06931028Phase 3
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingNCT06143956Phase 2
• A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06124807Phase 2Results posted
• Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityActive, not recruitingNCT07000955Phase 1/2
• A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruitingNCT06937749Phase 2
• A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）Active, not recruitingNCT06884293Phase 3
• A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingNCT06862908Phase 2
• A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderCompletedNCT06817356Phase 2
• This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityCompletedNCT06536023Phase 1
• Efficacy of Mazdutide for Treating PCOSCompletedNCT06519656Phase 1/2
• A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityCompletedNCT06184568Phase 3
• A Study of IBI362 9 mg in Chinese Adults With ObesityActive, not recruitingNCT06164873Phase 3
• A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsCompletedNCT05815680Phase 1
• Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentCompletedNCT05793450Phase 1
• A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseCompletedNCT05628311Phase 3
• A Study of LY3305677 in Participants With Obesity Or OverweightCompletedNCT05623839Phase 1
• A Study of IBI362 in Participants With Obesity or OverweightCompletedNCT05607680Phase 3
• A Study of IBI362 in Participants With Type 2 DiabetesCompletedNCT05606913Phase 3
• A Study of IBI362 in Chinese Patients With Type 2 DiabetesCompletedNCT04965506Phase 2
• A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsCompletedNCT04904913Phase 2
• Clinical Study of IBI362 in Healthy Chinese Male SubjectsCompletedNCT04773977Phase 1
• Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMCompletedNCT04466904Phase 1/2
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsCompletedNCT04440345Phase 1/2
• A Study of LY3305677 in Participants With Type 2 DiabetesCompletedNCT03928379Phase 1
• A Study of Multiple Doses of LY3305677 in Healthy ParticipantsCompletedNCT03325387Phase 1
• A Study of LY3305677 in Healthy ParticipantsCompletedNCT02972645Phase 1

← Mazdutide overview